INTRODUCTION
Tumors have a complex cellular ecology. Previous studies have shown that tumors consist not only of malignant cells but also of various stromal cell types (Lewis et al., 1995; Hanahan and Coussens, 2012) . The stromal cells in cancer can be divided into three subtypes: angiogenic vascular cells (AVCS), infi ltrating immune cells (IICs), and cancer-associated fi broblastic cells (CAFs) (Hanahan and Coussens, 2012) . Tumor growth is clearly dependent on angiogenesis, as tumors need to establish a blood vessel network to access oxygen and nutrients (Millan Nunez-Cortes, 1991; Cristofanilli et al., 2002; Folkman, 2007) . The contributions of stromal cells include resisting cell death, avoiding immune destruction, activating invasion, inducing angiogenesis, and sustaining proliferative signaling (Hanahan and Coussens, 2012) .
The macrophages found in tumors are usually termed tumor-associated macrophages (TAMs) (Lewis and Pollard, 2006) . The general understanding is that macrophages are subdivided into M1 (classically activated) and M2 (alternatively activated) phenotypes (Murdoch et al., 2008) . M1 macrophages show a pro-infl ammatory character, while M2 macrophages exhibit an immunosuppressive phenotype. TAMs often express many genes similar to those found in macrophages with the M2 phenotype and are thought to be M2-like macrophages (Murdoch et al., 2008) . A number of studies have shown that TAMs infl uence tumor angiogenesis (Qian and Pollard, 2010; Fukuda et al., 2012) . In human tumors, TAMs accumulate in poorly vascularized, necrotic areas and are also found surrounding blood vessels (Ferrara, 2010) . A large number of publications have indicated that high numbers of TAMs are a poor prognostic indicator in cancer (Bingle et al., 2002) . Lin and colleagues showed that decreasing macrophage infi ltration in tumors resulted in the inhibition of tumor angiogenesis & and delayed tumor development (Lin and Pollard, 2007) . Further studies have found that TAMs express a broad range of pro-angiogenic factors that positively regulate angiogenesis, including vascular endothelial growth factor (VEGF) (Bolat et al., 2006) , basic fi broblast growth factors (bFGF) (Bolat et al., 2006) , tumor necrosis factor (TNF-α), and transforming growth factor-β (TGF-β) (Luo et al., 2006) . These TAM-secreted factors explain the role of TAMs in tumor development. Because of their pivotal role in tumor growth, TAMs and their factors have been considered to be anticancer therapeutic targets. The blockade of colony stimulating factor-1 (CSF-1) signaling resulted in macrophage depletion in mammary tumors, reduced vascular density and improved responses to chemotherapy (Lin et al., 2001 ). Histidine-rich glycoprotein (HRG) can induce the reprogramming of TAMs, which has been shown to normalize vascular formations, resulting in a decrease in torturous vasculature, better pericyte coverage, less erratic blood fl ow, and improved responses to chemotherapy (Rolny et al., 2011) .
VEGF is an angiogenic factor that can bind to receptors to induce endothelial cell migration and form new blood vessels (Ferrara et al., 2003) . TAM-derived VEGF acts signifi cantly on angiogenesis and tumor development, whereas down-regulating VEGF levels induces antitumorigenesis (Bolat et al., 2006) . The deletion of the VEGF gene in macrophages decreases tumor angiogenesis (Stockmann et al., 2008) . Anti-bodies against VEGF exert a large inhibitory effect on tumor growth (Kim et al., 1993) . Cancer patients can currently receive anti-VEGF treatment, which results in a greater anti-tumor effect.
miRNAs are a class of small, non-coding RNAs that regulate gene expression at the post-transcriptional level (Bartel, 2004) . Previous studies have demonstrated that miRNAs are relevant to cancers (Esquela-Kerscher and Slack, 2006) , and anti-miRNA treatments have demonstrated anti-tumor effects on an experimental level (Kota et al., 2009) . Previous study has found that miRNAs can be packaged into microvesicles (MVs), which are membranous vesicles that are secreted from most cell types, and transferred to neighboring or distant cells, where these miRNAs can regulate the functions of the recipient cells (Zhang et al., 2010) . MVs have been utilized to transfer therapeutic RNAi to treat diseases (Alvarez-Erviti et al., 2011) . In our present study, we demonstrated that miR-150 serves as an oncomir by regulating the VEGF secretion of TAMs. Then, MVs were utilized as the means for delivering antisense RNA targeted to miR-150 into mice to treat tumors and decrease tumor development by infl uencing the level of VEGFs secreted by TAMs. Our present study proposed a new anti-tumor molecule and a new method for the transfer of antineoplastic drugs.
RESULTS

Microvesicle-delivered miR-150 promotes tumor development in vivo
MiR-150 is an immune-related miRNA that is up-regulated in the plasma with the occurrence of several types of cancers (Fig. 1A) . Thus, we hypothesized that miR-150 plays a role in tumorigenesis. To verify our hypothesis, we conducted the following experiments. We delivered miR-150 into mice using microvesicles to assess the effect of miR-150 on tumorigenesis. The human embryo kidney cell line 293T and its MVs contain a very low level of miR-150 (Zhang et al., 2010) ; thus, 293T MVs were chosen to serve as the carrier for miR-150. MiR-150 was over-expressed in the 293T cell line by transfecting mimicmiR-150 RNA; non-sense RNAs were also transfected into 293T cells to serve as the negative control. After transfection, MVs from 293T cells transfected with mimic-miR-150 RNA contained much higher levels of miR-150 compared with MVs from 293T cells transfected with ncRNA (Fig. 1B) . Mice were subcutaneously implanted with sarcoma cells (S-180) to create a tumor model, and 293T MVs with or without miR-150 were intravenously injected into the tumor mice models as described in Fig. 2A . The results showed that the injection of 293T MVs containing miR-150 increased the plasma miR-150 levels (Fig. 2B) . Tumor weight also dramatically increased after treatment with miR-150 (293T MV/miR-150) when compared with the saline group and the 293T/ncRNA group ( Fig. 2C and 2D ), suggesting that 293T MV-delivered exogenous miR-150 promotes tumor development in vivo.
VEGF is a very crucial factor in the process of tumor development. Tumors secrete VEGF to induce endothelial cell migration and the formation of new blood vessels. Serum VEGF levels were also assessed after the injection of miR-150. The ELISA results showed that VEGF levels increased in (Fig. 2E ). Taken together, these results demonstrate that miR-150 promoted tumor development and suggest that the promotion of tumor development may be mediated by VEGF.
MiR-150 targets TAMs and promotes VEGF secretion by TAMs
To further assess whether miR-150 has a positive effect on VEGF secretion, we performed an in vitro assay. Considering that most TAMs are thought to be M2-like and that TAMs are the major origin of VEGF during tumor development, we hypothesized that miR-150 may target TAMs and consequently alter the levels of VEGF secreted. To validate our hypothesis, the effect of miR-150 on TAMs was assessed. TAMs were isolated from mice sarcoma tissue. To verify whether TAMs from the sarcoma were M2-like macrophages, bone marrow cells were isolated from the femur and were polarized into M1 and M2 macrophages, which were used as the reference cells for TAMs. Markers that can effi ciently distinguish between M1 and M2 macrophages were tested. As we expected, the expression of these markers in TAMs was similar to M2 macrophages and differed from those observed in M1 macrophages, suggesting that the sarcoma-derived TAMs were M2-like macrophages (Fig. 3A) . MiR-150 is abundantly expressed in MVs derived from THP-1 human monocyte cells following AGE treatment (Fig. S1A) . Thus, to examine the effect of miR-150 on TAMs, AGE-treated THP-1 MVs that were rich in miR-150 were incubated with TAMs for 8 h, after which the medium was collected for use in an ELISA assay. The ELISA results showed that THP-1 MVs (AGE) dramatically enhanced VEGF secretion from TAMs (Fig. 3B ). Although miR-150 is abundantly expressed in THP-1 MVs, other contents in the MVs may be responsible for the promotion of VEGF secretion. To solve this problem and confi rm the role of miR-150, the following experiment was conducted. We knocked down miR-150 in THP-1 MVs by transfecting THP-1 cells with antisense oligonucleotides against miR-150 (anti-miR-150); ncRNAs were also transfected into THP-1 cells as a negative control. The transfected THP-1 cells were treated with AGE before medium collection. The results showed that miR-150 expression was reduced in the modified THP-1 MVs (Fig. S1B ). TAMs were incubated with these miR-150-defi cient MVs. After an 8 h incubation, the results revealed that the miR-150-defi cient MVs (THP-1 MV/ miR-150 def ) lost the ability to enhance VEGF secretion when compared to THP-1 MVs loaded with ncRNAs (THP-1 MV/ anti-ncRNA), suggesting that the promotion of VEGF secretion was mediated by miR-150 but not by other contents in the MVs (Fig. 3C ). Taken together, these results indicated that miR-150 
Microvesicle-delivered miR-150 inhibitor abolishes tumorigenesis and is proposed to be a potential therapeutic molecule against tumors
Because high levels of miR-150 promote tumor development, neutralizing miR-150 could potentially attenuate tumorigenesis. Taking advantage of the low level of miR-150 in 293T cells and 293T MVs, 293T MVs could be used as a carrier to transfer antisense RNA against miR-150 (anti-miR-150) into tumor models. We transfected 293T cells with antisense miR-150 RNA to load the MVs with the miR-150 inhibitor ( 293T MV/anti-miR-150). Mice were subcutaneously implanted with S-180 sarcoma cells to create a tumor model, and we treated this model with 293T MVs loaded with the miR-150 inhibitor or ncRNA, as depicted in Fig. 4A . The plasma miR-150 levels in mice treated with anti-miR-150 (293T MV/anti-miR-150) decreased signifi cantly compared with those from the ncRNA group and the control group (Fig. 4B) , indicating that the miR-150 inhibitor effectively decreased the plasma miR-150 levels of the tumor models. The VEGF levels in the plasma and tumor tissue also decreased when mice were treated with miR-150 antisense RNA (Fig. 4C) . Subsequently, the tumor weights from the 293T MV/anti-miR-150 group dramatically decreased ( Fig. 4D and 4E ), suggesting that tumor development was strongly restrained. Consistent with the previous result, the protein levels of VEGF in xenograft decreased dramatically with the treatment of miR-150 antisense RNA (Fig. 4F) . The results of the HE staining of paraffi n sections showed that tumors treated with the miR-150 inhibitor presented large areas of necrosis because of fewer palingenetic blood vessels (Fig. 4G) , further suggesting that angiogenesis and tumor development had been inhibited by the miR-150 inhibitor injection. The results of the immunohistochemical staining of paraffi n sections revealed that the expression levels of the endothelial cell marker CD31 were dramatically reduced after miR-150 inhibitor treatment (Fig. 4H) , suggesting that the migration of endothelial cells into the tumor was inhibited and that angiogenesis was inhibited in the tumor. Taken together, these results demonstrated that the down-regulation of miR-150 in a tumor model effi ciently inhibited VEGF secretion and consequently restrained tumor development, suggesting that miR-150 could be a potential therapeutic target in cancers and that MV-delivered anti-miR-150 could be a novel strategy to treat cancers.
Microvesicle-delivered miR-150 inhibitor prevents tumorigenesis
We also found that the inhibitor of miR-150 played a long-term function in regulating tumorigenesis in vivo. The experiment was conducted as depicted in Fig. 5A . The MVs containing the inhibitor of miR-150 were injected into mice via the tail vein prior to the mice being implanted with sarcoma cells. After 7 days, the plasma miR-150 and VEGF levels decreased dramatically in mice receiving miR-150 inhibitor treatment (293T MV/antimiR-150) compared with mice treated with saline or ncRNA (293T MV/anti-ncRNA) ( Fig. 5B and 5C ). The tumor weights from the anti-miR-150 injection group (293T MV/anti-miR-150) were lower than those from mice that were injected with 293T MV/ncRNA or saline ( Fig. 5D and 5E ). The result of the HE staining of paraffi n sections showed a decrease in angiogenesis in tumors from mice treated with the miR-150 inhibitor (293T MV/anti-miR-150) compared with those from the other two groups (Fig. 5F ). The immunohistochemical staining of paraffi n sections showed that CD31 expression was reduced in tumors from mice treated with the inhibitor of miR-150 (293T MV/anti- S a li n e 2 9 3 T M V / a n t i-n c R N A 2 9 3 T M V / a n t i-m iR -1 5 0 1.5
1.0 0.5 0.0 Relative intensity ** S a li n e 2 9 3 T M V / a n t i-n c R N A 2 9 3 T M V / a n t i-m iR -1 5 0 D Protein Cell & protein levels, HIF1A transcriptional activity, and VEGF mRNA levels under nonhypoxic conditions (Baek et al., 2005) . We also found that THP-1-derived MVs contained VEGF, which raised the issue of whether the VEGF in the MVs or miR-150 was responsible for the increased levels of VEGF. Through calculation, we found that the proportion of VEGF contained in the MVs was only 1.5% of the increased VEGF in medium, and the other 98.5% of increased VEGF was contributed by the effects of exogenous miR-150 (Fig. S1C) . Great progress has been made in developing therapeutic strategies that target TAMs and VEGF to treat cancer (Kim et al., 1993) . Several studies have revealed that TAMs are a very critical cell group in tumor tissue and that TAMs contribute greatly to tumorigenesis and the protection of tumors from therapy (McDonnell et al., 2003) . VEGF inhibition represses tumor angiogenesis, and this result has led to the clinical utilization of VEGF inhibitors to treat cancer (Warren et al., 1995; Presta et al., 1997) . In our present study, we used a microvesicledelivered antagonucleotide against miR-150 to treat tumors. After the injection, VEGF levels decreased because of the down-regulation of miR-150 (Fig. 4C) , and tumor growth was abolished by anti-miR-150 treatment (Fig. 4D) . Through the angiogenic morphogenesis results, we found that angiogenesis was attenuated after antisense injection ( Fig. 4F and 4G) . Thus, we concluded that the miR-150 antisense caused the anesis of tumor development by down-regulating VEGF. This method provides a new, potential target to treat cancer, and the function of miRNAs in cancer development should not be ignored.
Microvesicles, a class of membrane vesicles with a diameter of 30-1000 nm, contain shedding vesicle and exosome (Chen et al., 2012) . They are secreted by most cell types in vitro (Valadi et al., 2007) . MVs have been utilized for the delivery of therapeutic RNAi and are considered to be a more effective, advantageous method than other options. Compared with the delivery strategies of viruses, lipid nanoparticles and polymeric nanoparticles, MVs present some major advantages. MVs are a natural carrier and are not subject to attack by antibodies, complements or opsonins in circulation. Other methods are prone to be cleared or trigger unwanted immune responses (van den Boorn et al., 2011) . In our present study, MVs delivered the antagonucleotide for miR-150 into tumors effi ciently and repressed tumor development, further suggesting that MVs are the perfect carrier for transferring therapeutic small RNA. Furthermore, we found that the function of the injected antisense continued for quite a long time. Seven days after the injection, miR-150 was maintained at a low level in the plasma, and VEGF levels and tumor development were also repressed ( Fig. 5B-D) , demonstrating that the antisense was still functional in vivo. In this process, MVs may act as a protector for the inner antisense and allow the antisense to exist and act for a long time.
An increasing body of research has revealed the critical role of miRNAs in the process of tumor development and demonstrated that miRNAs can serve as therapeutic targets. Our premiR-150), suggesting that MV-delivered anti-miR-150 inhibited endothelial cell migration and angiogenesis in the tumors (Fig. 5G) . Taken together, these results demonstrated that the preemptive neutralization of miR-150 may alter the microenvironment of tumors and prevent subsequent tumorigenesis. The inhibitor of miR-150, protected by MVs, may survive and contribute to the regulation of tumor development over a longterm period.
DISCUSSION
During tumor development, tumor cells secrete chemoattractants to ensure the ongoing recruitment of monocytes into tumors, including some types of growth factors, such as VEGF, placenta growth factor (PIGF), and CSF-1 (Coffelt et al., 2009) . TAMs exhibit several characteristics of M2-polarized macrophages and promote tumor development by promoting angiogenesis and lymphangiogenesis, sustaining proliferative signaling and resisting cell death (Fukuda et al., 2012) . Our present study focused on the role of TAMs in the regulation of angiogenesis, largely via their production of VEGF. MiRNAs are a class of classic molecule that regulates tumor development. The term oncomir is specifi cally used to reference miRNAs that have critical functions in tumor development (Goga and Benz, 2007) . MiR-150 is an immune-related miRNA, and, for the fi rst time, the present study has found that miR-150 promotes tumorigenesis (Fig. 2C) . MiR-150 also promotes increased levels of VEGF in plasma (Fig. 2E) . Considering the large role VEGF plays in the induction of angiogenesis and tumor development, the significant promotion of tumor growth by miR-150 may be mediated by increased VEGF levels. TAMs are a major source of VEGF, which binds to receptors on endothelial cells to promote migration and budding (Bolat et al., 2006) . Thus, we proposed the hypothesis that TAMs may be the target cell of miR-150 during tumor development. In the present study, our results showed that exogenous miR-150 can increase the VEGF secretion by TAMs in vitro, revealing that miR-150 acts as a promotion factor in tumor development by regulating the VEGF secretion of TAMs ( Fig. 3B and 3C ). VEGF is not the direct target of miR-150, and miR-150 may target other upstream proteins involved in VEGF regulation. We predicted the target genes of miR-150 using Targetscan (http://www.targetscan.org/) and found that the inhibitor of growth family member 4 (ING4) is a very perfect target. It is well known that ING4 is a tumor suppressor for it intervenes the activity of hypoxia inducible factor (HIF) which has an important positive role in angiogenesis and tumorigenesis. HIF promote tumor angiogenesis by inducing VEGF and other factors (Ozer et al., 2005; Colla et al., 2007) . Thus, the up-regulation of VEGF by miR-150 may be mediated by ING4 (Brahimi-Horn and Pouyssegur, 2006) . Another predicted target of miR-150 by miRnada (http:// www.microma.org/) is OS9, which is an essential component of a multiprotein complex that regulates HIF1A levels in an oxygen-dependent manner (Baek et al., 2005) . It is reported that knockdown of OS9 by RNA interference increased HIF1A armpits of the animals. The tumor sizes were measured using a caliper and the tumor weights were determined after the tumors were separated from the animals.
Bone marrows were isolated from 8-week-old mice by fl ushing their femurs. The cells were suspended and maintained in RPMI 1640 media, supplemented with 10% FBS (Gibco) and 800 pg/mL mice M-CSF. Bone marrow cells were differentiated into non-polarized macrophages (M0) after 7 days. M0 cells were treated with 1 μg/mL LPS and 20 ng/mL IFN-γ to polarize them into classically activated macrophages (M1), or treated with 20 ng/mL IL-4 to polarize them into alternatively activated macrophages (M2).
Primary tumor-associated macrophage cells were isolated from the S-180 mouse sarcomas. Briefl y, solid tumors were shredded and disaggregated by exposure to 0.3% collagenase IV (Invitrogen, CA, USA) for 40 min at 37°C; 10 6 cells/mL were seeded in 60-mm dishes (Corning, Tewksbury, MA). After 12 h of incubation, non-adherent cells were washed away, and adherent cells were maintained.
MV isolation
MVs were isolated from cell culture medium by differential centrifugation, according to previous publications (Valadi et al., 2007; Skog et al., 2008) . After removing cells and other debris by centrifugation at 300 g and 3000 g, the supernatant was centrifuged at 110,000 g for 70 min (all steps were performed at 4°C). MVs were collected from the pellet and resuspended in PBS.
Cell transfection with scrambled negative control RNA, mimic-miR-150 RNA, and anti-miR-150 RNA Synthetic RNA molecules, including mimic-miR-150, anti-miR-150, and scrambled negative control oligonucleotides (mimic-ncRNA or anti-ncRNA), were purchased from Ambion (Austin, TX). THP-1 cells and 293T cells were seeded in 75 cm 2 flasks (Corning) and were transfected the following day using Lipofectamine 2000 (Invitrogen), according to the manufacturer's instructions. To over-express miR-150 in 293T cells, 750 pmol of mimic-miR-150 RNA or scrambled negative control RNA was used. To knockdown miR-150, 750 pmol of antimiR-150 RNA or scrambled negative control anti-miRNA (anti-ncRNA) was used. Cells and media were harvested 48 h after transfection.
RNA isolation and quantitative RT-PCR
The total RNA of cells was extracted using TRIzol Reagent (Invitrogen), according to the manufacturer's recommended protocols. Quantitative RT-PCR of mature miRNA was performed on an ABI 7900 (Applied Biosystems; Foster City, CA) instrument using the Taqman miRNA probes (Applied Biosystems). Gene Quantitative RT-PCR was performed on an ABI 7900 machine, and the primers used were purchased from Invitrogen. The primers used for macrophage marker genes were as follows: TNF-α: 5′-ACGGCATGGATCTCAAA-GAC-3′ (forward primer) and 5′-AGATAGCAAATCGGCTGACG-3′ (reverse primer); Nos2: 5′-CCAAGCCCTCACCTACTTCC-3′ (forward primer) and 5′-CTCTGAGGGCTGACACA-3′ (reverse primer); Arg1: 5′-CTCCAAGCCAAAGTCCTTAGAG-3′ (forward primer) and 5′-AG-GAGCTGTCATTAGGGACATC-3′ (reverse primer); and Msr2: 5′-AAA-GAAAGCCCGAGTCCC-3′ (forward primer) and 5′-TGCCCAAGGA-GATAGCAAGA-3′ (reverse primer).
ELISA assay
The VEGF levels in cell supernatants were measured using specifi c enzyme-linked immunosorbent assays. Briefl y, 2 mL cell-free supernatant (each sample) from TAMs was harvested from 10 5 cells after 8-hour incubations, and VEGF levels were determined using an ELISA kit (Invitrogen), following the manufacturer's instructions. Data were representative of 3 independent experiments.
Western blotting
The levels of VEGF protein in xenograft were quantifi ed by Western blot analysis using antibodies against VEGF (147, Santa Cruz). Normalization was conducted by blotting the same samples with an antibody against GAPDH (6C5, Santa Cruz).
Hematoxylin and eosin staining
The tumors were fi xed in 4% paraformaldehyde, embedded in paraffi n, sectioned, and then stained with hematoxylin and eosin. To perform a quantitative analysis, the numbers of erythrocyte-fi lled blood vessels (capillary density) were counted in 5 independent fi elds from three sections.
Immunohistochemistry
The tumors were fi xed in 4% paraformaldehyde, embedded in paraffi n, sectioned, and then stained with DBE-conjugated anti-CD31 antibodies (Abcam, MA, USA). Quantitative analysis was conducted by quantifying the fl uorescence intensity from fi ve sections.
Statistical analysis
Statistical analysis was performed using a T-test. Data are presented
